Monograph
S01EC04 - Brinzolamide |
Propably not porphyrinogenic |
PNP |
Rationale
sulfonamide derivative preferentially distributed to red blood cells. Probably insignificant hepatic load. Very long final elimination time from erythrocytes.
Chemical description
sulfonamide used in eyedrops (10 mg/mL) to reduce the intraocular pressure in glaucoma. Isopropyl ester prodrug to an active prostaglandine analogue. Conversion to the active acid form takes place through hydrolysis. Reaches circulation in topical application but due to effective bindnding to erytrocyte carboanhydrases the plasma levels are very low, often lower than 10 ng/ml. Long elimination time in blood; half time about six months. Metabolized by CYPs 3A4 (major enzyme), 2A6, 2C8, 2C9. Brinzolamide and its N-desethyl metabolite is excreted in urine, 20 % as metabolites.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
© NAPOS 2025